Shining a new light on the path from biological understanding to transformative medicines.
Xaira brings together the tools, technologies and ways of working needed to fully harness the power of AI for drug discovery. Co-founded and incubated by ARCH Venture Partners and Foresite Labs, Xaira has three core elements: advanced AI research, expansive data generation and robust therapeutic product development.
Our AI capabilities range from fundamental computational methods development, to the application of these methods to biological discovery, molecule design and clinical development. Our computational core is built on foundational work by our co-founder, Nobel Laureate Dr. David Baker, and his team at the Institute for Protein Design at the University of Washington that leverages AI to design entirely new proteins from scratch, enabling the creation of medicines against molecular targets that have been resistant to other approaches. Xaira is advancing their groundbreaking models while developing new models that can illuminate biological understanding and translate it into new medicines.
AI can’t learn without the right data. Xaira’s computational advances are underpinned by a robust data platform that can generate, integrate and learn from multidimensional data sets that span from molecular to human scales. Our team of experts in functional genomics and proteomics are pioneering new approaches to gain unprecedented insights from these data into the causal relationships behind disease.
In the hands of an experienced team of drug developers, our computational and data platforms fuel robust therapeutic product development across multiple modalities for a pipeline of differentiated therapeutics. And we are simultaneously working to shift drug discovery from an empirical science to a precise engineering discipline. Every lab and clinical experiment we conduct is a vehicle for rich data generation, allowing the drug development process itself to continually inform new model development and improvement.